Home » Newsletters » BioWorld Science

BioWorld Science

April 3, 1998

View Archived Issues

Company Profile: Biosource Technologies

NIH offers malaria vaccine technology for licensing

New inhibitors of cell adhesion in development at Kao

Gliatech's H3 antagonists show potential for treating obesity

Genetix cancer gene therapy approach gives promising results in preliminary studies

SuperVent phase I/II trial going well; first part of two-part study concluded

IND granted for Enzo Biochem's HGTV43 genetic antisense therapy for AIDS

Neovastat efficacy reported at AACR

Eisai files NDA for Aciphex, novel treatment for GERD and ulcers

New acne treatment option now available in Canada

Immunex and ArQule form alliance to discover new antiinflammatory drug candidates

Neurogen prepares new class of brain GABA receptor ligands

U.S. patent issues for GenVec's advanced gene therapy vectors

Centrally active adrenergic agents in development at Pierre Fabre

Pfizer discovers compounds useful as cytokine and cell adhesion molecule inhibitors

Immunomedics discovers immunoangioplasty technology, seeks corporate partners

Positive results obtained with apoptosis suppressant in heart attack

Redux adverse effects reviewed at ACC

New prenyl transferase inhibitors in development at BMS

Novel antimicrobial compounds for Clostridium infections described by Abbott

Stehlin Foundation describes new camptothecins with improved stability

Abbott/TAP discover safer LHRH antagonists

FDA approves Actonel for Paget's disease

FDA says Integrilin is approvable

Orphan Medical announces Xyrem clinical trial results

Dual-action agent for BPH developed at Zeria

CGP-60474: selective protein tyrosine kinase inhibitor for cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...